FDA
-
-
-
-
-
-
-
NeuroSense reports biomarker findings from small Alzheimer's PrimeC trial
-
-
-
-
-
-
-
NeuroSense receives Brazilian patent for PrimeC drug composition
-
-
-
-
-
-
-
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
-
-
-
-
-
-
-
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
-
-
-
-
-
-
-
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
-
-
-
-
-
-
-
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
-
-
-
-
-
-
-
Neurosense Therapeutics (NRSN) Regains Nasdaq Compliance
-
328,151 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

